×

Biotech and Pharmaceuticals Medicine

  • *Attack first took hold in Ukraine, spread worldwide. FRANKFURT/ MOSCOW/ KIEV, June 28- A new cyber virus spread from Ukraine to wreak havoc around the globe on Wednesday, crippling thousands of computers, disrupting ports from Mumbai to Los Angeles and halting production at a chocolate factory in Australia. The virus is believed to have first taken hold on Tuesday...

  • We need to be very careful about what we ban in America: John Kamp

    John Kamp, executive director at Coalition for Healthcare Communication, and Dr. Aaron Kesselheim, Hardvard Medical School professor of medicine, discuss whether cutting drug advertising will improve heath care costs in government.

  • *Attack first took hold in Ukraine, spread worldwide. FRANKFURT/ MOSCOW/ KIEV, June 28- A new cyber virus spread from Ukraine to wreak havoc around the globe on Wednesday, crippling thousands of computers, disrupting ports from Mumbai to Los Angeles and halting production at a chocolate factory in Australia. The virus is believed to have first taken hold on Tuesday...

  • FDA's Scott Gottlieb on generic drug competition

    FDA Commissioner Scott Gottlieb discusses pricing and competition in the pharmaceutical industry and what policy steps can be taken to promote low-cost generic drugs.

  • Cleveland Clinic's Tony Cosgrove: Senate health-care bill doesn't tackle rising costs

    Cleveland Clinic CEO Dr. Tony Cosgrove discusses why he's against the Senate's health-care bill as it stands right now and what effect it would have on hospitals should it pass.

  • AMSTERDAM, June 28- Dutch healthcare company Philips has agreed to buy U.S.-based Spectranetics Corp, a maker of devices to treat heart disease, for 1.9 billion euros including debt, as it expands its image-guided therapy business. Philips will pay Spectranetics shareholders $38.50 per share, a 27 percent premium to their closing price on June 27.

  • *Wave of disruption started in Russia and Ukraine. MOSCOW/ KIEV/ WASHINGTON, June 28- A major global cyber attack disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware that infected more than 300,000 computers last month. Businesses in the Asia-Pacific region reported some...

  • *Wave of disruption started in Russia and Ukraine. MOSCOW/ KIEV/ WASHINGTON, June 27- A major global cyber attack on Tuesday disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware that last month infected more than 300,000 computers. It included code known as "Eternal Blue," which cyber...

  • *Wave of disruption started in Russia and Ukraine. MOSCOW/ KIEV/ WASHINGTON, June 27- A major global cyber attack on Tuesday disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware that last month infected more than 300,000 computers. It included code known as "Eternal Blue," which cyber...

  • *Wave of disruption started in Russia and Ukraine. MOSCOW/ KIEV/ WASHINGTON, June 27- A major global cyber attack dubbed "GoldenEye" or "Petya" on Tuesday disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware virus that last month infected more than 300,000 computers.

  • *MYSTIC lung cancer trial results expected any day. *U.S. near-term put contracts outweigh call options 3.3 times. LONDON/ NEW YORK, June 27- Investors in drugmaker AstraZeneca have taken defensive positions in the options market ahead of eagerly awaited results of a major trial of a lung cancer treatment, which are due any day now.

  • TRENTON, N.J.— Merck& Co. said Tuesday that a new type of cholesterol drug reduced heart attacks, deaths and other complications of heart disease in a huge, late-stage study. The positive result was a welcome surprise because three previous experimental drugs of the same type had failed. Cheap generics don't cut those risks enough for many people, while two new...

  • A patient is monitored in an examination room inside the Clinical Decision Unit at Kaiser Permanente's Capitol Hill Medical Center in Washington, D.C.

    Older Americans are being unfairly targeted in the Republicans’ health-care bill, AARP's David Certner told CNBC.

  • Potbotics CEO David Goldstein (L) and co-founder Baruch Goldstein

    There are more than 30,000 branded strains of marijuana out there, and Potbot's technology sorts through them all to tell which

  • The drug, Adcetris, co-developed with Japan's Takeda Pharmaceutical Co Ltd, met the goal of helping blood cancer patients live longer without worsening their condition. The relatively modest improvement of about 5 percent could generate cost concerns among insurers, SunTrust Bank analyst Yatin Suneja said. Adcetris is approved in the United States to treat...

  • June 26- Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening. The relatively modest improvement of about 5 percent could generate cost concerns among payers, but the benefit from removing bleomycin...

  • June 26- Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening. The relatively modest improvement of about 5 percent could generate cost concerns among payers, but the benefit from removing bleomycin...

  • June 19- Seattle Genetics Inc said it would halt a late-stage study of its drug to treat a type of leukemia in older patients following a "higher rate" of deaths in patients on the drug compared with those on a placebo. Shares of the U.S. drug developer fell as much as 11 percent to $57.40 in early trading on Monday, but recouped some losses to be down about 3.7 percent.

  • June 26- Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening. Adcetris is already approved in the United States to treat patients with classical Hodgkin's lymphoma, who have already received a stem...

  • *Roche plans 2017 FDA filing. ZURICH, June 26- Roche's investigational hemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Nearly 63 percent of patients receiving emicizumab experienced zero treated bleeds, compared...